Advertisement
Product › Details
brodalumab (AMG 827)
Next higher product group | IL-17 inhibitor | |
Status | 2017-02-01 registration start | |
Organisation | Leo Pharma A/S | |
Group | Leo Pharma (Group) | |
Organisation 2 | Amgen Inc. (Nasdaq: AMGN) | |
Group | Amgen (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for IL-17 inhibitor
- [1] Scinai Immunotherapeutics Ltd.. (9/19/23). "Press Release: Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering". Jerusalem....
- [2] Scinai Immunotherapeutics Ltd.. (9/15/23). "Press Release: Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering". Jerusalem....
- [3] Scinai Immunotherapeutics Ltd.. (9/6/23). "Press Release: BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics". Jerusalem....
- [4] BiondVax Pharmaceuticals Ltd.. (6/5/23). "Press Release: BiondVax Signs Exclusive License Agreement for Development and Commercialization of a Novel anti-IL-17 Antibody". Jerusalem....
- [5] DiCE Molecules SV, Inc.. (1/8/21). "Press Release: DiCE Molecules Announces $80 Million Series C Financing. Jake Simson, Ph.D., Joins Board of Directors". South San Francisco, CA....
- [6] Leo Pharma A/S. (7/20/17). "Press Release: LEO Pharma Receives Marketing Authorisation for Kyntheum (brodalumab), a New Biologic for the Treatment of Moderate-to-severe Plaque Poriasis in the European Union". Ballerup....
- [7] AstraZeneca plc. (5/19/17). "Press Release: Brodalumab Receives Positive CHMP Opinion for the Treatment of Adult Patients with Moderate-to-severe Plaque Psoriasis"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top